A detailed history of Creative Planning transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Creative Planning holds 14,300 shares of BMRN stock, worth $906,906. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,300
Previous 11,825 20.93%
Holding current value
$906,906
Previous $973,000 3.29%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$69.02 - $93.84 $170,824 - $232,254
2,475 Added 20.93%
14,300 $1.01 Million
Q2 2024

Aug 15, 2024

BUY
$74.43 - $92.22 $39,001 - $48,323
524 Added 4.64%
11,825 $973,000
Q1 2024

May 10, 2024

SELL
$83.81 - $99.0 $83 - $99
-1 Reduced 0.01%
11,301 $987,000
Q4 2023

Feb 14, 2024

BUY
$76.22 - $98.51 $208,537 - $269,523
2,736 Added 31.94%
11,302 $1.09 Million
Q3 2023

Nov 16, 2023

BUY
$85.07 - $94.48 $43,130 - $47,901
507 Added 6.29%
8,566 $757,000
Q2 2023

Jul 21, 2023

BUY
$86.68 - $100.3 $93,094 - $107,722
1,074 Added 15.38%
8,059 $698,000
Q1 2023

May 15, 2023

BUY
$87.74 - $117.27 $14,301 - $19,115
163 Added 2.39%
6,985 $679,000
Q4 2022

Feb 10, 2023

BUY
$80.93 - $108.63 $43,054 - $57,791
532 Added 8.46%
6,822 $706,000
Q3 2022

Nov 03, 2022

BUY
$82.16 - $96.94 $4,354 - $5,137
53 Added 0.85%
6,290 $533,000
Q2 2022

Aug 15, 2022

BUY
$71.48 - $86.85 $196,141 - $238,316
2,744 Added 78.56%
6,237 $517,000
Q1 2022

May 16, 2022

SELL
$74.28 - $92.69 $96,712 - $120,682
-1,302 Reduced 27.15%
3,493 $269,000
Q4 2021

Feb 11, 2022

BUY
$71.72 - $91.47 $1,506 - $1,920
21 Added 0.44%
4,795 $424,000
Q3 2021

Nov 10, 2021

BUY
$74.77 - $85.47 $18,767 - $21,452
251 Added 5.55%
4,774 $369,000
Q2 2021

Aug 04, 2021

SELL
$75.51 - $84.79 $33,073 - $37,138
-438 Reduced 8.83%
4,523 $377,000
Q1 2021

Apr 30, 2021

SELL
$74.73 - $90.69 $44,613 - $54,141
-597 Reduced 10.74%
4,961 $375,000
Q4 2020

Jan 29, 2021

SELL
$72.61 - $90.2 $42,041 - $52,225
-579 Reduced 9.43%
5,558 $487,000
Q3 2020

Nov 05, 2020

BUY
$71.87 - $131.03 $73,307 - $133,650
1,020 Added 19.93%
6,137 $467,000
Q2 2020

Jul 23, 2020

SELL
$79.55 - $124.22 $64,674 - $100,990
-813 Reduced 13.71%
5,117 $631,000
Q1 2020

May 05, 2020

SELL
$71.37 - $96.85 $269,350 - $365,511
-3,774 Reduced 38.89%
5,930 $501,000
Q4 2019

Jan 30, 2020

SELL
$64.27 - $86.37 $5,912 - $7,946
-92 Reduced 0.94%
9,704 $820,000
Q3 2019

Nov 01, 2019

BUY
$67.4 - $85.11 $8,896 - $11,234
132 Added 1.37%
9,796 $660,000
Q2 2019

Jul 26, 2019

SELL
$80.35 - $93.9 $420,230 - $491,097
-5,230 Reduced 35.11%
9,664 $828,000
Q1 2019

Apr 24, 2019

SELL
$84.2 - $98.62 $264,556 - $309,864
-3,142 Reduced 17.42%
14,894 $1.32 Million
Q4 2018

Feb 01, 2019

BUY
$80.14 - $106.07 $1.07 Million - $1.42 Million
13,398 Added 288.87%
18,036 $1.54 Million
Q3 2018

Oct 25, 2018

SELL
$93.92 - $105.72 $47,617 - $53,600
-507 Reduced 9.85%
4,638 $450,000
Q2 2018

Jul 20, 2018

SELL
$76.01 - $99.03 $9,957 - $12,972
-131 Reduced 2.48%
5,145 $485,000
Q1 2018

Apr 18, 2018

SELL
$77.67 - $92.63 $71,145 - $84,849
-916 Reduced 14.79%
5,276 $428,000
Q4 2017

Jan 17, 2018

BUY
$80.76 - $95.13 $171,938 - $202,531
2,129 Added 52.4%
6,192 $552,000
Q3 2017

Oct 17, 2017

BUY
$80.6 - $94.95 $327,477 - $385,781
4,063
4,063 $378,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.